Antileukaemic effect of <scp>PI</scp>3<scp>K</scp>‐m<scp>TOR</scp> inhibitors in acute myeloid leukaemia‐gene expression profiles reveal <scp>CDC</scp>25<scp>B</scp> expression as determinate of pharmacological effect

Abstract excerpt

Acute myeloid leukaemia (AML) is a heterogeneous malignancy. Intracellular signalling through the phosphatidylinositol 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) pathway is important for regulation of cellular growth and metabolism, and inhibitors of this pathway is considered for AML treatment. Primary human AML cells, derived from 96 consecutive adult patients, were examined. The effects of two...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Myeloid Leukemia Research
• Share to PI3K/AKT/mTOR signaling in cancer